Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • NTRK fusion detection across three assays and 29,000 tumors
    Meeting Abstract

    Solomon, J.; Sireci, N.; Drilon, A.; Mullaney, K.; Benayed, R.; Ladanyi, M.; Hechtman, J.
    Laboratory Investigation (2019)

    Fulltext@MSK | Save
  • Evaluation of H3K27me3 expression as a marker of EZH2 activation in SMARCA4/SMARCA2-deficient tumors and candidate biomarker for trials of EZH2 inhibitors
    Meeting Abstract

    Kezlarian, B.; Montecalvo, J.; Sauter, J.; Travis, W.; Gounder, M.; Rudin, C.; Ladanyi, M.; Namakydoust, A.; Rekhtman, N.
    Laboratory Investigation (2019)

    Fulltext@MSK | Save
  • Acute lung injury pattern is a frequent histologic finding in lung tissue following immune checkpoint inhibitor therapy
    Meeting Abstract

    Golden, A.; Imran, S.; Feinstein, M.; Hellmann, M.; Plodkowski, A.; Rekhtman, N.; Rizvi, H.; Travis, W.; Stover, D.; Sauter, J.
    Laboratory Investigation (2019)

    Fulltext@MSK | Save
  • Importance of distinguishing adenocarcinoma and squamous cell carcinoma in assessment of pathologic response after neoadjuvant chemotherapy
    Meeting Abstract

    Emoto, K.; Qu, Y.; Zheng, H.; Aly, R.; Eguchi, T.; Chaft, J.; Tan, K. S.; Kris, M.; Adusumilli, P.; Travis, W.
    Laboratory Investigation (2019)

    Fulltext@MSK | Save
  • Genomic profiling of prostate cancer with EGFR family gene alterations-potential of clinical and therapeutic implications
    Meeting Abstract

    Momeni Boroujeni, A.; Gupta, S.; Li, B.; Al-Ahmadie, H.; Solit, D.; Reuter, V.; Gopalan, A.; Arcila, M.; Fine, S.; Ladanyi, M.; more...
    Laboratory Investigation (2019)

    Fulltext@MSK | Save
  • Activity of larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase, in TRK fusion breast cancers
    Meeting Abstract

    Meric-Bernstam, F.; Shukla, N.; Peled, N.; Landman, Y.; Onitilo, A.; Montez, S.; Ku, N. C.; Hyman, D. M.; Drilon, A.; Hong, D. S.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study
    Meeting Abstract

    Paik, P.; Cortot, A.; Felip, E.; Sakai, H.; Mazieres, J.; Horn, L.; Griesinger, F.; Bruns, R.; Scheele, J.; Straub, J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Activity of larotrectinib in TRK fusion lung cancer
    Meeting Abstract

    Drilon, A.; Kummar, S.; Moreno, V.; Patel, J.; Lassen, U.; Rosen, L.; Childs, B. H.; Nanda, S.; Cox, M. C.; Ku, N. C.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer
    Meeting Abstract

    Planchard, D.; Li, B. T.; Murakami, H.; Shiga, R.; Lee, C. C.; Wang, K.; Jänne, P. A.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001
    Meeting Abstract

    Shaw, A.; Riely, G. J.; Bang, Y. J.; Kim, D. W.; Camidge, D. R.; Shapiro, G. I.; Usari, T.; Wang, S. C.; Wilner, K.; Clark, J. W.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save